SCHEMBL71574

SCHEMBL71574

CC(C)c1ccc(NCC(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
USP5 P45974 1/20 0.49
RAB9A P51151 6/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
KIF11 P52732 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
HIF1A Q16665 1/20 0.47
NPC1 O15118 4/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13773412 0.85 CA12 (0.49) CA12CA1CA2CA7HPGD
Hydrochloric Acid SCHEMBL5776301 0.84 HPGD (0.53) CA12CA1CA2CA7HPGD
SCHEMBL5692310 0.83 ALDH1A1 (0.44) CA12CA1CA2HPGDSMN1; SMN2
SCHEMBL4409854 0.83 KIF11 (0.54) CA12CA1CA2CA7HPGD
SCHEMBL19501377 0.81 CA12 (0.53) CA12CA1CA2CA7HPGD
SCHEMBL133676 0.81 HPGD (0.54) CA12CA1CA2CA7HPGD
SCHEMBL9112981 0.81 ACP3 (0.37) CA12CA1CA2CA7HPGD
SCHEMBL13531978 0.80 CA12 (0.46) CA12CA1CA2CA7HPGD
SCHEMBL11957885 0.79 SMN1; SMN2 (0.46) CA12CA1CA2CA7HPGD
SCHEMBL9564259 0.79 ALDH1A1 (0.37) CA12CA1CA2HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030977-A2 NOVEL MELANOCORTIN ANALOGS SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) 2024-02-08 WO claimed
CN-113480485-B 1,2, 4-triaryl-1, 2, 4-triazoles compound and synthetic method thereof 甘肃农业大学 2023-04-07 CN claimed
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC. 2015-06-18 US claimed
EP-2850095-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA Pharmaceuticals, Inc. (US) 2015-03-25 EP claimed
WO-2013172954-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC (US) 2013-11-21 WO claimed
US-20030143664-A1 Products of manufacture and processes for peptide synthesis DIVERSA CORPORATION (US) 2003-07-31 US claimed
WO-2003048189-A2 PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS DIVERSA CORPORATION (US) 2003-06-12 WO claimed
US-12617818-B2 Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them UNIVERSITY OF NORTH TEXAS (US) 2026-05-05 US disclosed
US-20260116948-A1 T CELL RECEPTOR CONSTRUCTS AND USES THEREOF BIONTECH US INC (US) 2026-04-30 US disclosed
US-20260115288-A1 T CELL MANUFACTURING COMPOSITIONS AND METHODS BIONTECH US INC (US) 2026-04-30 US disclosed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4729094-A2 Modulators of complement activity UCB Holdings, Inc. (US) 2026-04-22 EP disclosed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
US-5508384-A NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS NEW YORK UNIVERSITY (US) 1996-04-16 US disclosed
WO-1995022561-A2 PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1995-08-24 WO disclosed
WO-1995020397-A1 PHOSPHACAN, NUCLEIC ACIDS ENCODING THEREOF AND ANTIBODIES THERETO NEW YORK UNIVERSITY (US) 1995-08-03 WO disclosed
WO-1995013828-A1 BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS NEW YORK UNIVERSITY (US) 1995-05-26 WO disclosed
WO-1995013291-A1 NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE NEW YORK UNIVERSITY (US) 1995-05-18 WO disclosed
WO-1994003601-A9 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN 1994-03-31 WO disclosed
WO-1994003601-A2 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN NEW YORK UNIVERSITY (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115288-A1 T CELL MANUFACTURING COMPOSITIONS AND METHODS CD14, CD4, IL2RA CA12 3617/4885CA1 4189/4885CA2 4480/4885
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS KLKB1, KLK1, KLK5 CA12 1373/4885CA1 1427/4885CA2 2333/4885
US-12617818-B2 Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them MYLK2, TNNC1, MYOF CA12 3526/4885CA1 3702/4885CA2 1762/4885
US-20260116948-A1 T CELL RECEPTOR CONSTRUCTS AND USES THEREOF MICA, IGSF11, IGLV6-57 CA12 4663/4885CA1 4602/4885CA2 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.